• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺导管原位癌的肿块切除术

Lumpectomy surgery for large ductal carcinoma in situ.

作者信息

Padilla Daniela Bresciani, Tsai Jacqueline, Beck Amanda Sutherland, Wapnir Irene L

机构信息

Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.

Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive H3625, Stanford, CA, 94305, USA.

出版信息

Breast Cancer Res Treat. 2025 May;211(1):51-58. doi: 10.1007/s10549-025-07621-w. Epub 2025 Feb 10.

DOI:10.1007/s10549-025-07621-w
PMID:39928263
Abstract

PURPOSE

Breast-conserving surgery for larger ductal carcinoma in situ (DCIS) remains limited. We compare the attempted use and success rates of lumpectomy surgery in patients with DCIS measuring ≥ 4 cm versus < 4 cm.

METHODS

A retrospective review was conducted using the institutional tumor registry to identify cases of pure DCIS that were surgically treated from 2015 to 2022. Clinical-pathological data were abstracted from electronic medical records. Pathologic tumor size on initial surgery was used to define the two cohorts. Comparisons of variables were made using Chi-square and ANOVA tests.

RESULTS

A total of 669 patients, 84% (562) with tumors measuring < 4 cm and 16% (107) ≥ 4 cm were identified. Lumpectomy was the initial surgery performed for 89% of women with lesions measuring < 4 cm on preoperative imaging studies compared to 64% of those ≥ 4 cm. Overall, 461 (92.9%) of 496 in the < 4 cm succeeded at lumpectomy compared to 36 (56.3%) of 64 in the ≥ 4 cm group. Re-excision lumpectomies or mastectomy were performed in 27% and 44% of the < 4 cm and ≥ 4 cm subgroups. Lumpectomy was achieved for 70% of women with tumors in the 4 to 5.9 cm range compared to 33% in the 6-7.9 cm and the ≥ 8 cm groups. There were no local recurrences in the ≥ 4 cm group at an average of 4.4 years follow-up.

CONCLUSION

Lumpectomy is a viable option for many patients with DCIS ≥ 4 cm, especially those measuring < 6 cm, though repeat re-excisions may be required after initial attempt.

摘要

目的

对于较大的导管原位癌(DCIS),保乳手术的应用仍然有限。我们比较了肿瘤大小≥4 cm与<4 cm的DCIS患者行乳房肿块切除术的尝试率和成功率。

方法

使用机构肿瘤登记处进行回顾性研究,以确定2015年至2022年接受手术治疗的纯DCIS病例。从电子病历中提取临床病理数据。首次手术时的病理肿瘤大小用于定义两个队列。使用卡方检验和方差分析对变量进行比较。

结果

共确定669例患者,其中84%(562例)肿瘤大小<4 cm,16%(107例)≥4 cm。在术前影像学检查中,89%肿瘤大小<4 cm的女性首次手术为乳房肿块切除术,而肿瘤大小≥4 cm的女性这一比例为64%。总体而言,<4 cm组496例中有461例(92.9%)乳房肿块切除术成功,而≥4 cm组64例中有36例(56.3%)成功。<4 cm和≥4 cm亚组分别有27%和44%的患者进行了再次切除乳房肿块切除术或乳房切除术。肿瘤大小在4至5.9 cm范围内的女性,70%实现了乳房肿块切除术,而在6 - 7.9 cm组和≥8 cm组中这一比例为33%。在平均4.4年的随访中,≥4 cm组无局部复发。

结论

对于许多肿瘤大小≥4 cm,尤其是<6 cm的DCIS患者,乳房肿块切除术是一种可行的选择,尽管初次尝试后可能需要再次切除。

相似文献

1
Lumpectomy surgery for large ductal carcinoma in situ.乳腺导管原位癌的肿块切除术
Breast Cancer Res Treat. 2025 May;211(1):51-58. doi: 10.1007/s10549-025-07621-w. Epub 2025 Feb 10.
2
The safety of multiple re-excisions after lumpectomy for breast cancer.乳腺癌保乳术后多次再切除术的安全性。
Ann Surg Oncol. 2011 Dec;18(13):3797-801. doi: 10.1245/s10434-011-1802-4. Epub 2011 Jun 1.
3
Should New "No Ink On Tumor" Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins.新的“肿瘤无墨水”乳房肿瘤切除术切缘指南是否应应用于导管原位癌(DCIS)?一项使用刮除腔切缘的回顾性研究。
Ann Surg Oncol. 2016 Oct;23(11):3453-3458. doi: 10.1245/s10434-016-5251-y. Epub 2016 May 20.
4
Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy.乳房导管原位癌保乳手术及放疗的病理与技术考量
Ann Oncol. 1999 Aug;10(8):883-90. doi: 10.1023/a:1008339113607.
5
The Effect of Lumpectomy and Cavity Shave Margin Status on Recurrence and Survival in Breast-Conserving Surgery.保乳手术中肿瘤局部广泛切除术(腔镜下切除术)和切缘状态对复发和生存的影响。
Am Surg. 2023 Mar;89(3):424-433. doi: 10.1177/00031348211030464. Epub 2021 Jul 1.
6
Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature.乳腺导管原位癌女性患者的诊断年龄与预后:文献综述
J Clin Oncol. 2002 Jun 1;20(11):2736-44. doi: 10.1200/JCO.2002.07.137.
7
Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.保乳术或乳房切除术治疗导管原位癌的女性中放疗与生存的关系。
JAMA Netw Open. 2018 Aug 3;1(4):e181100. doi: 10.1001/jamanetworkopen.2018.1100.
8
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.不进行放疗的手术切除治疗乳腺导管原位癌:ECOG-ACRIN E5194研究的12年结果
J Clin Oncol. 2015 Nov 20;33(33):3938-44. doi: 10.1200/JCO.2015.60.8588. Epub 2015 Sep 14.
9
Short term safety of oncoplastic breast conserving surgery for larger tumors.针对较大肿瘤的肿瘤整形保乳手术的短期安全性
Eur J Surg Oncol. 2017 Apr;43(4):665-671. doi: 10.1016/j.ejso.2016.11.021. Epub 2016 Dec 18.
10
Excision alone for small size ductal carcinoma in situ of the breast.单纯切除治疗小尺寸乳腺导管原位癌。
Breast. 2014 Oct;23(5):586-90. doi: 10.1016/j.breast.2014.05.025. Epub 2014 Jun 23.

本文引用的文献

1
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.DCIS 大小和边缘状态与治疗后乳腺癌发病风险的关系:多国、汇总队列研究。
BMJ. 2023 Oct 30;383:e076022. doi: 10.1136/bmj-2023-076022.
2
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.主动监测与低危 DCIS 治疗:LORD 试验中的女性偏好。
Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4.
3
Surgeon Factors Influencing Breast Surgery Outcomes: A Scoping Review to Define the Modern Breast Surgical Oncologist.
影响乳房手术结果的外科医生因素:定义现代乳房外科肿瘤学家的范围综述。
Ann Surg Oncol. 2023 Aug;30(8):4695-4713. doi: 10.1245/s10434-023-13472-w. Epub 2023 Apr 10.
4
The Landmark Series-Ductal Carcinoma in Situ: The Evolution of Treatment.里程碑系列——导管原位癌:治疗的演变
Ann Surg Oncol. 2023 Jun;30(6):3206-3214. doi: 10.1245/s10434-023-13370-1. Epub 2023 Apr 6.
5
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.保乳治疗下大乳腺导管原位癌(DCIS)病变女性的长期结局。
Breast Cancer Res Treat. 2022 Feb;192(1):223-233. doi: 10.1007/s10549-021-06488-x. Epub 2022 Jan 27.
6
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.随机 III 期临床试验评估手术切除后低危导管原位癌的放疗:NRG 肿瘤学/RTOG9804 的长期报告。
J Clin Oncol. 2021 Nov 10;39(32):3574-3582. doi: 10.1200/JCO.21.01083. Epub 2021 Aug 18.
7
National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons.加拿大外科医生在乳腺导管原位癌的检查、研究和手术管理方面的国家差异。
Curr Oncol. 2021 Mar 29;28(2):1366-1375. doi: 10.3390/curroncol28020130.
8
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).COMET(手术与监测和内分泌治疗比较)试验:一项针对低危导管原位癌(DCIS)的 III 期随机对照临床试验。
BMJ Open. 2019 Mar 12;9(3):e026797. doi: 10.1136/bmjopen-2018-026797.
9
Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.广泛纯导管原位癌≥4cm 行保乳治疗与乳房切除术的局部复发比较
Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):381-388. doi: 10.1016/j.ijrobp.2018.09.022. Epub 2018 Sep 22.
10
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.外科肿瘤学会-美国放射肿瘤学会-美国临床肿瘤学会关于导管原位癌保乳手术联合全乳照射切缘的共识指南。
J Clin Oncol. 2016 Nov 20;34(33):4040-4046. doi: 10.1200/JCO.2016.68.3573. Epub 2016 Oct 31.